<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFAMYLON- mafenide acetateÂ powder, for solutionÂ </strong><br>Mylan Institutional Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_ca0d863c-4892-4b7e-9ba1-8c8219c1e932"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Mafenide acetate, USP is a synthetic antimicrobial agent designated chemically as Î±-amino-<span class="Italics">p</span>-toluenesulfonamide monoacetate. It has the following structural formula:</p>
<div class="Figure">
<a name="id195"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=570ce479-d902-4394-bbae-41dfe16c5485&amp;name=0b896d25-e1d5-4e09-84b6-7a278d6e40bd-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">7</span>H<span class="Sub">10</span>N<span class="Sub">2</span>O<span class="Sub">2</span>Sâ—?C<span class="Sub">2</span>H<span class="Sub">4</span>O<span class="Sub">2</span>   M.W. 246.29 </p>
</div>
<p>Mafenide acetate, USP is a white, crystalline powder which is freely soluble in water.</p>
<p>SULFAMYLONÂ® For 5% Topical Solution is provided in packets containing 50 g of sterile mafenide acetate to be reconstituted in 1000 mL of Sterile Water for Irrigation, USP or 0.9% Sodium Chloride Irrigation, USP. After mixing, the solution contains 5% w/v of mafenide acetate. The solution is an antimicrobial preparation suitable for topical administration. <span class="Bold">The solution is not for injection.</span> The reconstituted solution may be held up to 28 days after preparation if stored in unopened containers. ONCE A CONTAINER IS OPENED, ANY UNUSED PORTION SHOULD BE DISCARDED AFTER 48 HOURS. Store the reconstituted solution at 20Â° to 25Â°C (68Â° to 77Â°F). Limited storage periods at 15Â° to 30Â°C (59Â° to 86Â°F) are acceptable.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_4515d8be-dc86-4019-8e52-91dde830468c"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_e28324fc-e391-4cda-85e6-d83a6575d048"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The mechanism of action of mafenide is not known, but is different from that of the sulfonamides. Mafenide is not antagonized by pABA, serum, pus or tissue exudates, and there is no correlation between bacterial sensitivities to mafenide and to the sulfonamides. Its activity is not altered by changes in the acidity of the environment. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of the 5% topical solution is approximately 340 mOsm/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ae69898-b11e-4384-9aa0-c900df1a1f8c"></a><a name="section-2.2"></a><p></p>
<h2>Absorption and Metabolism</h2>
<p class="First">Applied topically, mafenide acetate diffuses through devascularized areas. Approximately 80% of a mafenide acetate dose is delivered to burned tissue over four hours following topical application of the 5% solution. Following application of mafenide acetate cream and solution, peak mafenide concentrations in human burned skin tissue occur at two and four hours, respectively. Peak tissue concentrations are similar following administration of the solution or cream. Once absorbed, mafenide is rapidly converted to an inactive metabolite (p-carboxybenzenesulfonamide) which is cleared through the kidneys. Clinical studies have shown that when applied topically to <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> as an 11.2% mafenide acetate cream, blood levels of the parent drug peaked at 2 hours following application, ranging from 26 to 197 Âµg/mL for single doses of 14 to 77 g of mafenide acetate. Metabolite levels peaked at 3 hours, ranging from 10 to 340 Âµg/mL. Twenty-four hours after application, combined parent and metabolite blood levels had fallen to pretreatment levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a9d2445-4ac6-4a7b-9f86-6cb8f156ae1f"></a><a name="section-2.3"></a><p></p>
<h2>Antimicrobial Activity</h2>
<p class="First">Mafenide acetate exerts broad bacteriostatic action against many gram-negative and gram-positive organisms, including <span class="Italics">Pseudomonas aeruginosa</span> and certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of anaerobes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0c5fc139-6dd4-4abd-a911-7535121e58be"></a><a name="section-2.4"></a><p></p>
<h2>In Vitro Cytotoxicity</h2>
<p class="First">Data from <span class="Italics">in vitro</span> studies on cell culture suggests that mafenide acetate may have a deleterious effect on human keratinocytes. The clinical significance of this information is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_fc018bb6-f69a-45c0-840c-11ea04673737"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">SULFAMYLON<span class="Sup">Â®</span> For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> when used under moist dressings over meshed autografts on excised burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_da6de006-0be2-4df2-8c6d-2d69ec45f41d"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">SULFAMYLON<span class="Sup">Â®</span> For 5% Topical Solution is contraindicated in patients who are hypersensitive to mafenide acetate. It is not known whether there is cross sensitivity to other sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_ce6de3bd-5646-42e2-afa7-b7d1029648da"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Fatal <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> with <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenide acetate.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_0b963e6d-eea7-4316-8119-04b8b58ef63e"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_28127805-ed0e-4e2e-b756-7dfcde98b01f"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Mafenide acetate and its metabolite, <span class="Italics">p</span>-carboxybenzenesulfonamide, inhibit carbonic anhydrase, which may result in <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, usually compensated by <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>. In the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, high blood levels of mafenide acetate and its metabolite may exaggerate the carbonic anhydrase inhibition. Therefore, close monitoring of acid-base balance is necessary, particularly in patients with extensive second-degree or partial-thickness <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> and in those with pulmonary or renal dysfunction. Some burn patients treated with mafenide acetate have also been reported to manifest an unexplained syndrome of masked <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> with resulting <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span> (slightly alkaline blood pH, low arterial pCO<span class="Sub">2</span>, and decreased total CO<span class="Sub">2</span>); change in arterial pO<span class="Sub">2</span> is variable. The etiology and significance of these findings are unknown.</p>
<p>Mafenide acetate should be used with caution in burn patients with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>Fungal colonization may occur concomitantly with reduction of bacterial growth in the burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>. However, systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> through the infected burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> is rare.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4adbc0c6-d815-4c66-bbd1-a821165c8d89"></a><a name="section-6.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term animal studies have been performed to evaluate the carcinogenic potential of mafenide acetate; however, the drug did not induce mutations in L5178Ymouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells at the TK locus.</p>
<p>Animal studies have not been performed to evaluate the potential effects of mafenide acetate on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_f387143b-122f-40c1-9c38-118a5539b6b9"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_ea128ac6-a0d3-43de-8726-ac8d132bdf8f"></a><a name="section-6.3.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects. Pregnancy Category C.</span></h3>
<p class="First">A teratology study performed in rats using oral doses of up to 600 mg/kg/day revealed no evidence of harm to the fetus due to mafenide acetate. There are no adequate data regarding the potential reproductive toxicity of mafenide acetate in a non-rodent species, nor are there adequate and well controlled studies in pregnant women. Mafenide acetate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_7bb586ec-442a-4c2c-847a-930064544b37"></a><a name="section-6.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether mafenide acetate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from mafenide acetate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_a6a5ccd6-023b-4ec6-9614-e7a3a9376194"></a><a name="section-6.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of SULFAMYLON<span class="Sup">Â®</span> For 5% Topical Solution have been established in the age groups 3 months to 16 years.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_fa76a90a-9886-4585-8ab8-b3a64f566d1e"></a><a name="section-6.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No studies have been conducted to specifically examine the effects of mafenide acetate on burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> in geriatric patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a351917e-58bd-4e19-87c0-d34f7e3f0525"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In the clinical setting of severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, it is often difficult to distinguish between an adverse reaction to mafenide acetate and burn sequelae. In a clinical study of pediatric patients with acute <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> requiring autografts who received SULFAMYLON<span class="Sup">Â®</span> (mafenide acetate, USP) For 5% Topical Solution in addition to double antibiotic solution (DAB) <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> therapy (neomycin sulfate 40 mg and polymyxin B 200,000 units/liter), the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (4.6%) and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> (2.8%) in the group which received SULFAMYLON<span class="Sup">Â®</span> 5% Solution was not different from that experienced with (DAB) dressings alone (5.7% and 1.3%, respectively).</p>
<p>From other clinical settings, a single case of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> and a single case of an acute attack of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> have been reported following therapy with mafenide acetate. Fatal <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> with <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with mafenide acetate. The following adverse reactions have been reported with topical mafenide acetate therapy:</p>
<p><span class="Bold">Dermatologic and Allergic: </span><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (often localized to the area covered by the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> dressing), <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, skin maceration from prolonged wet dressings, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</p>
<p><span class="Bold">Respiratory or Metabolic: </span><span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, decrease in pCO<span class="Sub">2</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, increase in serum chloride.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_58144ddb-0246-4e44-8e9f-0c8d58cc6baf"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Single oral doses of 2000 mg/kg of mafenide acetate as a 5% solution did not cause mortality or clinical symptoms of toxicity in rats.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c1a5b648-59b7-4d9e-b37a-2aa2fa5bbc97"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3a6eff9-9aa6-46cc-a168-6b980afdbc57"></a><a name="section-9.1"></a><p></p>
<h2>SULFAMYLON<span class="Sup">Â®</span> For 5% Topical Solution</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c45d800d-15c8-4ac7-b4df-fa06feed59af"></a><a name="section-9.1.1"></a><p></p>
<h3><span class="Bold">Directions for Preparation of the Solution</span></h3>
<p class="First">SULFAMYLON<span class="Sup">Â®</span> (mafenide acetate) For 5% Topical Solution is supplied as a sterile powder and is to be reconstituted with Sterile Water for Irrigation, USP or 0.9% Sodium Chloride Irrigation, USP. Aseptic techniques should be observed during preparation of the solution. Premeasured quantities of 50 g of mafenide acetate powder are provided in sterile packets. The entire quantity of SULFAMYLON<span class="Sup">Â®</span> should be emptied into a suitable container which contains 1000 mL of Sterile Water for Irrigation, USP or 0.9% Sodium Chloride Irrigation, USP and mixed until completely dissolved. The reconstituted solution may be held up to 28 days after preparation if stored in unopened containers. ONCE A CONTAINER IS OPENED, ANY UNUSED PORTION SHOULD BE DISCARDED AFTER 48 HOURS. Store the reconstituted solution at 20Â° to 25Â°C (68Â° to 77Â°F). Limited storage periods at 15Â° to 30Â°C (59Â° to 86Â°F) are acceptable. <span class="Bold">Not for Injection - For Topical Use Only.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdd50df3-5f2f-4a8d-8891-63f60246c4e4"></a><a name="section-9.1.2"></a><p></p>
<h3><span class="Bold">Directions for Use of the Solution</span></h3>
<p class="First">The grafted area should be covered with one layer of fine mesh gauze. An eight-ply burn dressing should be cut to the size of the graft and wetted with SULFAMYLON<span class="Sup">Â®</span> (mafenide acetate, USP) For 5% Topical Solution using an irrigation syringe and/or irrigation tubing until leaking is noticeable. If irrigation tubing is used, the tubing should be placed over the burn dressing in contact with the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> and covered with a second piece of eight-ply dressing. The irrigation dressing should be secured with a bolster dressing and wrapped as appropriate. The gauze dressing should be kept wet. In clinical studies, this has been accomplished by irrigating with a syringe or injecting the solution into the irrigation tubing every 4 hours or as necessary. If irrigation tubing is not used, the gauze dressing may be moistened every 6-8 hours or as necessary to keep wet.</p>
<p><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> dressings may be left undisturbed, except for the irrigations, for up to five days. Additional soaks may be initiated until graft take is complete. Maceration of skin may result from wet dressings applied for intervals as short as 24 hours. Treatment is usually continued until autograft vascularization occurs and healing is progressing (typically occurring in about 5 days). Safety and effectiveness have not been established for longer than 5 days for an individual grafting procedure.</p>
<p>If allergic manifestations occur during treatment with SULFAMYLON<span class="Sup">Â®</span> (mafenide acetate, USP) For 5% Topical Solution, discontinuation of treatment should be considered. If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> occurs and becomes difficult to control, particularly in patients with pulmonary dysfunction, discontinuing the soaks with the mafenide acetate solution for 24 to 48 hours may aid in restoring acid-base balance (see <a href="#i4i_precautions_id_0b963e6d-eea7-4316-8119-04b8b58ef63e">PRECAUTIONS</a> section). Dressing changes and monitoring the site for bacterial growth during this interruption should be adjusted accordingly.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_537b3a28-56cd-4d3d-9b6a-463155f9b6d8"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">SULFAMYLONÂ® (mafenide acetate, USP) For 5% Topical Solution is available in packets (NDC 51079-624-84) containing 50 g of sterile mafenide acetate to be prepared using 1000 mL Sterile Water for Irrigation, USP or 0.9% Sodium Chloride Irrigation, USP. (See <a href="#i4i_section_id_c45d800d-15c8-4ac7-b4df-fa06feed59af">DOSAGE AND ADMINISTRATION: SULFAMYLONÂ® For 5% Topical Solution: Directions for Preparation of the Solution</a>.) The packets are supplied as follows:</p>
<p>Carton of five 50 g packets<br>NDC 51079-624-85</p>
<p><span class="Bold">Recommended Storage:</span></p>
<p>Packets - Store PACKETS in a dry place at room temperature 15Â° to 30Â°C (59Â° to 86Â°F).</p>
<p>Prepared Solution - Store SOLUTION at 20Â° to 25Â°C (68Â° to 77Â°F) with excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F). [See USP Controlled Room Temperature.]</p>
<p>The solution may be held for up to 28 days if stored in unopened containers.</p>
<p>ONCE A CONTAINER IS OPENED, ANY UNUSED SOLUTION MUST BE DISCARDED WITHIN 48 HOURS.</p>
<p>Keep this and all medications out of the reach of children.</p>
<p><span class="Bold">Mylan Institutional Inc.</span><br>Rockford, IL  61103  U.S.A.</p>
<p>095.4<br>REVISED JUNE 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7813d83f-8d82-413e-8efc-240a98ff0014"></a><a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5% TOPICAL SOLUTION </h1>
<p class="First"><span class="Bold">NDC 51079-624-85</span></p>
<p><span class="Bold">STERILE </span></p>
<p><span class="Bold">SULFAMYLON<span class="Sup">Â®</span></span><br><span class="Bold">(mafenide acetate, USP)</span><br><span class="Bold">for 5% Topical Solution</span></p>
<p><span class="Bold">Not for Injection</span><br><span class="Bold">Solution for Topical Use Only</span></p>
<p><span class="Bold">Net Wt. 50 grams sterile powder per packet</span></p>
<p><span class="Bold">Store PACKET in a dry place at room temperature</span><br><span class="Bold">15Â° to 30Â°C (59Â° to 86Â°F).</span></p>
<p><span class="Bold">DIRECTIONS FOR PREPARATION AND STORAGE OF <br>THE SOLUTION - Do not use if packet is opened. <br>Observe aseptic technique when preparing solution. <br></span>This packet contains 50 grams of sterile mafenide acetate, <br>USP. Open packet and empty entire contents into a suitable <br>container containing 1000 mL of either Sterile Water for <br>Irrigation, USP or 0.9% Sodium Chloride, USP. Mix until <br>completely dissolved. This yields a 5% solution of mafenide <br>acetate, USP. The solution may be held for up to 28 days if <br>stored in unopened containers. ONCE A CONTAINER IS <br>OPENED, ANY UNUSED SOLUTION MUST BE DISCARDED <br>WITHIN 48 HOURS.</p>
<p><span class="Bold">Store SOLUTION at 20Â° to 25Â°C (68Â° to 77Â°F) </span><br><span class="Bold">excursions 15Â° to 30Â°C (59Â° to 86Â°F).</span></p>
<p><span class="Bold">Usual Dosage:</span> For dosage and usage information see <br>accompanying prescribing information.</p>
<p><span class="Bold">Keep this and all medications out of the reach of<br>children.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â 5 Packets</span></p>
<p><span class="Bold">Mylan Institutional Inc.</span><br>Rockford, IL 61103 U.S.A.</p>
<p>565.5</p>
<div class="Figure">
<a name="id-1477985257"></a><img alt="Sulfamylon for 5% Topical Solution" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=570ce479-d902-4394-bbae-41dfe16c5485&amp;name=image-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFAMYLONÂ 		
					</strong><br><span class="contentTableReg">mafenide acetate powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51079-624</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MAFENIDE ACETATE</strong> (MAFENIDE) </td>
<td class="formItem">MAFENIDE ACETATE</td>
<td class="formItem">50Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-624-85</td>
<td class="formItem">5  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51079-624-84</td>
<td class="formItem">1  in 1 PACKET; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019832</td>
<td class="formItem">06/05/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Institutional Inc.
							(039615992)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8fda7ed8-0525-4105-bb74-a4bbdcc93f2c</div>
<div>Set id: 570ce479-d902-4394-bbae-41dfe16c5485</div>
<div>Version: 5</div>
<div>Effective Time: 20120605</div>
</div>
</div>Â <div class="DistributorName">Mylan Institutional Inc.</div></p>
</body></html>
